Carastock.

Cara Therapeutics Inc’s ( CARA) price is currently down 34.15% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $6.58. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $7.40. Year to date, Cara Therapeutics Inc’s stock is ...

Carastock. Things To Know About Carastock.

A high-level overview of Cara Therapeutics, Inc. (CARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus.Cara Therapeutics stock was originally listed at a price of $12.91 in Jan 31, 2014. If you had invested in Cara Therapeutics stock at $12.91, your return over the last 9 years would have been -91.32%, for an annualized return of -23.79% (not including any dividends or dividend reinvestments). How much is Cara Therapeutics's stock price per ...Dec 1, 2023 · When is Cara Therapeutics's earnings date? Cara Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off last year's report dates. Learn more on CARA's earnings history.

Cara Therapeutics, Inc. Common Stock (CARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.CARA support price is $1.04 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CARA stock will trade within this expected range on the day.Cara Therapeutics (CARA) Company Description. Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic ...

218.25%. Free cash flow. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -8.64M. 47.45%. Get the latest Cara Therapeutics Inc (CARA ... Find out all the key statistics for Cara Therapeutics, Inc. (CARA), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

CARA and Weed heating up this could go anyway at the moment but strong volume and huge gap to fill on this chart but we have earnings coming out Monday after hours so …What's Happening with CARA Stock Today. Cara Therapeutics Inc (CARA) stock is down -3.55% while the S&P 500 is down -0.28% as of 2:22 PM on Thursday, Oct 19. CARA is down -$0.05 from the previous closing price of $1.41 on volume of 234,874 shares. Over the past year the S&P 500 is higher by 16.43% while CARA is down -86.11%.Nov 22, 2023 · Future criteria checks 2/6. Cara Therapeutics is forecast to grow earnings and revenue by 10.7% and 39.6% per annum respectively. EPS is expected to grow by 27.7% per annum. Return on equity is forecast to be -187% in 3 years. As of March 10, 2023, 4:00 PM CST, Cara Therapeutics Inc’s stock price was $6.06. Cara Therapeutics Inc is down 5.16% from its previous closing price of $6.39. During the last market session, Cara Therapeutics Inc’s stock traded between $6.24 and $6.71. Currently, there are 53.76 million shares of Cara Therapeutics Inc stock available for ...In 2022, CARA's revenue was $41.87 million, an increase of 81.81% compared to the previous year's $23.03 million. Losses were -$85.47 million, -3.35% less than ...

Who is on Cara Therapeutics's Insider Roster? The list of insiders at Cara Therapeutics includes Christopher Posner, Derek T Chalmers, Frederique Ph.D. Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly. Learn more on insiders at CARA.

Cara Therapeutics Stock Earnings. The value each CARA share was expected to gain vs. the value that each CARA share actually gained. Cara Therapeutics ( CARA) reported Q3 2023 earnings per share (EPS) of -$0.52, meeting estimates of -$0.52 by 0.60%. In the same quarter last year, Cara Therapeutics 's earnings per share (EPS) was -$0.43.

What happened. Shares of Cara Therapeutics ( CARA -5.11%) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study ...The current Cara Therapeutics [ CARA] share price is $1.09. The Score for CARA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ...Apr 29, 2021 · What happened. Shares of Cara Therapeutics ( CARA -5.11%) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study ... Mar 11, 2023 · Following the downgrade, the current consensus from Cara Therapeutics' eight analysts is for revenues of US$53m in 2023 which - if met - would reflect a sizeable 27% increase on its sales over the ... Nov 14, 2023 · The stock of Cara Therapeutics Inc (CARA) has seen a -11.28% decrease in the past week, with a -16.90% drop in the past month, and a -60.67% decrease in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.66% for CARA. 7 ngày trước ... Getty Images Carastock. Light therapy is a gold-standard treatment that has been trusted by derms and celebrities for decades. It was once ...

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus.Cara Therapeutics (CARA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known consensus ...See the latest Carasent ASA stock price (XOSL:CARA), related news, valuation, dividends and more to help you make your investing decisions.Earnings date. 13 Nov 2023. Forward dividend & yield. N/A (N/A) Ex-dividend date. N/A. 1y target est. 10.29. Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.Cara stock has gone in circles without any catalysts to help unlock value, but 2022 is full of growth catalysts. Click here to see why I think CARA is a good buy for investors.

Cara Therapeutics Inc ( CARA) has risen Tuesday morning, with the stock increasing 5.25% in pre-market trading to 3.41. CARA's short-term technical score of 10 indicates that the stock has traded less bullishly over the last month than 90% of stocks on the market. In the Biotechnology industry, which ranks 110 out of 146 industries, the stock ...CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by …

finance.yahoo.com - November 14 at 5:00 PM. Cara Therapeutics Stock (NASDAQ:CARA) Earnings Dates and Earning Calls. benzinga.com - November 14 at 7:53 AM. Cara Therapeutics GAAP EPS of -$0.52 beats by $0.01, revenue of $4.87M misses by $5.08M. msn.com - November 13 at 8:53 PM.As of Friday, March 03, Cara Therapeutics Inc’s CARA share price has surged by 4.90%, which has investors questioning if this is right time to sell.CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to ...Track Cara Therapeutics Inc (CARA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Notably, Cara Therapeutics actually ramped up its cash burn very hard and fast in the last year, by 128%, signifying heavy investment in the business. While that's concerning on it's own, the fact ...The average price recommended by analysts for Cara Therapeutics Inc (CARA) is $10.29, which is $9.33 above the current market price. The public float for CARA is 46.23M and currently, short sellers hold a 6.42% of that float. On November 24, 2023, CARA’s average trading volume was 599.48K shares. Top 5 EV Tech Stocks to Buy for 2023.Oct 23, 2023 · Cara Therapeutics Reports Second Quarter 2023 Financial Results. – 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA ® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS ... Cara Therapeutics Inc stock is down -23.46% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives CARA stock a score of 75 out of a possible 100.. That rank is mainly influenced by a fundamental score of 84. In addition to the average rating from Wall …Over the last four quarters, the company has surpassed consensus EPS estimates two times. Cara, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.26 ...6 brokerages have issued 1-year price targets for Cara Therapeutics' stock. Their CARA share price targets range from $4.00 to $25.00. On average, they expect the company's stock price to reach $15.86 in the next twelve months. This suggests a possible upside of 1,396.0% from the stock's current price.

Cara Therapeutics Stock (NASDAQ: CARA) stock price, news, charts, stock research, profile.

Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.

Cara Therapeutics Stock Forecast, CARA stock price prediction. Price target in 14 days: 1.492 USD. The best long-term & short-term Cara Therapeutics share ...Find the latest Cara Therapeutics, Inc. (CARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Cara Therapeutics Stock (NASDAQ: CARA) stock price, news, charts, stock research, profile.Pruritus is defined as an unpleasant sensation that provokes the desire to scratch, but we know it’s much more than that. Chronic pruritus can be a devastating, disabling, and burdensome condition that significantly impairs quality of life. The millions of people who suffer from pruritus deserve relief.According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00.This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Cara Therapeutics, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more. 1 minute.Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Nov 29, 2023 · The Cara Therapeutics stock price fell by -1.90% on the last day (Wednesday, 29th Nov 2023) from $0.98 to $0.96. During the last trading day the stock fluctuated 7.37% from a day low at $0.95 to a day high of $1.02. The price has fallen in 6 of the last 10 days and is down by -12.47% for this period. Volume has increased on the last day by 227 ... 13 Nov 2023. Forward dividend & yield. N/A (N/A) Ex-dividend date. N/A. 1y target est. 10.29. Press Releases. Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.

The current Cara Therapeutics [ CARA] share price is $1.09. The Score for CARA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.CARA has an Altman Z-Score of -9.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Cara Therapeutics, Inc. (CARA) stock, including valuation metrics, financial numbers, share information and more.Dec 1, 2023 · Who is on Cara Therapeutics's Insider Roster? The list of insiders at Cara Therapeutics includes Christopher Posner, Derek T Chalmers, Frederique Ph.D. Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly. Learn more on insiders at CARA. Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus.Instagram:https://instagram. day trade softwarebest forex strategyvanguard vnqinvest 100k All CARA Stock Technical Studies are available in different time frames. 5 Min 15 Minutes 30 Min Hourly 5 Hours Daily Weekly Monthly. Summary. Strong Sell. Sell. Neutral. Buy. Strong Buy. Strong Sell. synthetic biology stocksdividend mo CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by …What happened. Shares of Cara Therapeutics ( CARA -5.11%) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study ... ibkr vs tradestation Get the latest Cara Therapeutics Inc. (CARA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.CARA support price is $1.04 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CARA stock will trade within this expected range on the day.It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...